The concept of a receptor as a discrete molecular entity that transduces a chemical signal into a biological response is foundational to all of pharmacology. Drug receptors are overwhelmingly proteins, and they fall into four major structural and functional classes, each with distinct transduction mechanisms, time courses of action, and pharmacological exploitability. Knowing which receptor class a drug targets immediately predicts its signaling logic, its onset and duration of effect, and the categories of drugs that can act as its modulators.
G protein-coupled receptors (GPCRs, also called seven-transmembrane receptors or heptahelical receptors) constitute the largest and most pharmacologically exploited receptor superfamily, with over 800 members in the human genome and an estimated 30 to 40 percent of all approved drugs acting at this class.1 GPCRs share a common seven-transmembrane alpha-helical architecture. The extracellular domains and transmembrane helices form the ligand-binding pocket, while the intracellular loops and C-terminal tail couple to heterotrimeric G proteins composed of alpha, beta, and gamma subunits. Ligand binding induces a conformational change in the receptor that promotes exchange of guanosine diphosphate (GDP) for guanosine triphosphate (GTP) on the alpha subunit, leading to dissociation of the alpha subunit from the beta-gamma dimer. Both the GTP-bound alpha subunit and the free beta-gamma dimer can activate downstream effectors. The signal is terminated by intrinsic GTPase activity of the alpha subunit, which hydrolyzes GTP back to GDP, allowing reassembly of the inactive heterotrimer. The functional diversity of this receptor class arises from the variety of G protein alpha subunit isoforms: Gs stimulates adenylyl cyclase; Gi inhibits adenylyl cyclase and activates inwardly rectifying potassium channels; Gq activates phospholipase C (PLC); and G12/13 (the Rho-activating G protein subclass) activates Rho GTPases.12
Ligand-gated ion channels, also called ionotropic receptors, are transmembrane proteins in which the ion channel pore and the ligand-binding site are components of the same macromolecular complex. Ligand binding directly gates the channel open, producing ion flux within milliseconds. This makes ligand-gated ion channels the fastest-acting receptor class and the primary mediators of rapid synaptic transmission in the nervous system. The major subtypes include the nicotinic acetylcholine receptor (nAChR), which is a pentameric complex permeable to sodium and potassium; the gamma-aminobutyric acid type A (GABA-A) receptor, a pentameric chloride channel; the N-methyl-D-aspartate (NMDA) receptor and other ionotropic glutamate receptors; and the glycine receptor. Many clinically critical drugs act at these channels: benzodiazepines and barbiturates act at the GABA-A receptor, ketamine blocks the NMDA receptor channel pore, and succinylcholine activates the neuromuscular junction nAChR.23
Enzyme-linked receptors are single-pass or multi-pass transmembrane proteins in which the intracellular domain possesses intrinsic enzymatic activity or directly recruits enzymatic partners. The largest and most clinically important subclass is the receptor tyrosine kinase (RTK) family, which includes the receptors for insulin, epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and platelet-derived growth factor (PDGF). Ligand binding induces receptor dimerization, activation of the intracellular kinase domains by transphosphorylation of tyrosine residues, and creation of docking sites for downstream signaling proteins bearing Src homology 2 (SH2) domains. This activates multiple parallel signaling pathways including the Ras/MAPK (mitogen-activated protein kinase) pathway, the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, and the signal transducer and activator of transcription (STAT) pathway. Receptor guanylyl cyclases, which generate cyclic guanosine monophosphate (cGMP) in response to atrial natriuretic peptide (ANP), and transforming growth factor-beta (TGF-beta) receptors with serine/threonine kinase activity represent additional enzyme-linked receptor classes.1
Nuclear Receptors. Nuclear receptors are intracellular, soluble transcription factors that are activated by lipophilic ligands able to cross the cell membrane. They include steroid hormone receptors (glucocorticoid receptor, mineralocorticoid receptor, androgen receptor, estrogen receptor, progesterone receptor), thyroid hormone receptors, vitamin D receptor, retinoic acid receptor, and the peroxisome proliferator-activated receptors (PPARs). In the unliganded state, many steroid receptors are retained in the cytoplasm in an inactive complex with heat shock proteins (HSPs). Ligand binding causes HSP (heat shock protein) dissociation, receptor dimerization, nuclear translocation, and binding to specific DNA (deoxyribonucleic acid) sequences called hormone response elements (HREs), resulting in transcriptional activation or repression of target genes. Because nuclear receptor signaling requires gene transcription and de novo protein synthesis, the onset of action is slow (hours to days) compared to membrane receptor classes. This time course is pharmacologically consequential: the anti-inflammatory effects of glucocorticoids, the therapeutic effects of thyroid hormone replacement, and the antiresorptive effects of estrogen on bone all reflect genomic nuclear receptor signaling operating over days.14
GPCRs: milliseconds to minutes; second messenger cascades (cAMP, IP3/DAG, cGMP); beta-adrenergic agonists, opioids, muscarinic drugs, dopamine agonists. Ligand-gated ion channels: milliseconds; direct ion flux; benzodiazepines, barbiturates, nicotine, ketamine. Enzyme-linked receptors (RTKs): minutes to hours; tyrosine phosphorylation cascades; insulin, imatinib, trastuzumab, sunitinib. Nuclear receptors: hours to days; gene transcription changes; glucocorticoids, thyroid hormone, estrogens, androgens, PPARgamma agonists (thiazolidinediones).
The quantitative relationship between a drug and its receptor is governed by the law of mass action. Understanding the equilibrium dissociation constant, the kinetics of receptor occupancy, and the relationship between occupancy and effect is essential for interpreting drug potency, predicting competitive interactions, and understanding clinical dosing principles.
Drug-receptor binding is a reversible, bimolecular interaction described by the equilibrium: Drug (D) + Receptor (R) ⇌ Drug-Receptor Complex (DR). The forward reaction, association, occurs with a rate constant kon (units: M-1s-1), while the reverse reaction, dissociation, occurs with a rate constant koff (units: s-1). At equilibrium, the rate of complex formation equals the rate of dissociation: kon[D][R] = koff[DR]. The equilibrium dissociation constant (Kd) is defined as koff/kon, with units of molar concentration (M). A lower Kd indicates higher affinity: a drug with a Kd of 1 nM has 1000-fold greater affinity for its receptor than a drug with a Kd of 1 micromolar (uM). The reciprocal of the Kd, the affinity constant (Ka = kon/koff), is also used, with higher Ka values indicating higher affinity. In radioligand binding assays, the Kd is determined experimentally as the concentration of drug at which 50 percent of receptors are occupied at equilibrium, a relationship that follows directly from the law of mass action.5
Fractional Occupancy. The fraction of receptors occupied by a drug at any given free drug concentration [D] is described by the Hill-Langmuir equation: occupancy = [D] / ([D] + Kd). When [D] equals the Kd, exactly 50 percent of receptors are occupied. When [D] greatly exceeds the Kd, receptor occupancy approaches 100 percent asymptotically. This equation predicts a hyperbolic relationship between drug concentration and receptor occupancy. On a linear concentration axis, the curve rises steeply at low concentrations and plateaus as receptors become saturated. When plotted on a log concentration axis, the relationship becomes a sigmoidal (S-shaped) curve that is more useful for visualizing pharmacodynamic relationships across several orders of magnitude of drug concentration, which is the relevant range for clinical pharmacology.56
Kinetics of Association and Dissociation. The rate of drug-receptor complex formation in vivo is determined by both kon and drug concentration, while the rate of dissociation depends only on koff and is concentration-independent. The dissociation rate constant koff determines the residence time of the drug on the receptor: the half-life of the drug-receptor complex equals ln(2)/koff. Drugs with slow koff values (long receptor residence times) maintain their pharmacological effect even as plasma concentrations fall, a phenomenon termed kinetic selectivity or target residence time. This principle has important clinical implications: the extended duration of action of tiotropium (a long-acting muscarinic antagonist, LAMA) relative to ipratropium reflects its dramatically slower koff from the M3 (muscarinic receptor subtype 3) muscarinic receptor, not simply a higher affinity. Similarly, covalent or pseudo-irreversible binding, where koff approaches zero, results in a duration of effect that is determined by receptor synthesis rather than drug concentration, as seen with irreversible aspirin acetylation of cyclooxygenase (COX) and the organophosphate inhibition of acetylcholinesterase (AChE).56
Clark Occupancy Theory and Its Limitations. A.J. Clark's classical occupancy theory, proposed in the 1920s, assumed that the magnitude of a drug's effect was directly proportional to the fraction of receptors it occupied: effect = occupancy x Emax, where Emax is the maximum possible effect. This model elegantly predicted the hyperbolic concentration-effect relationships observed for many drugs. However, it failed to account for two observations that became apparent with larger data sets: first, that some drugs could produce maximal effects while occupying only a small fraction of available receptors (the concept of receptor reserve); and second, that structurally similar drugs occupying the same fraction of receptors could produce different magnitudes of maximal effect (differences in intrinsic efficacy). These discrepancies led to the development of more sophisticated receptor theories, including the concept of intrinsic efficacy introduced by Stephenson and the operational model of agonism formulated by Black and Leff, which form the conceptual basis for modern drug discovery and the development of partial agonists and biased agonists as therapeutic agents.67
Kd = koff/kon. Lower Kd = higher affinity. At [D] = Kd, exactly 50% receptor occupancy. Kd is not the same as EC50 (which reflects the concentration producing 50% of maximum effect) unless receptor reserve is absent and the system is linear. High-affinity drugs (low Kd) can produce effects at lower plasma concentrations, but do not necessarily produce greater maximal effects than lower-affinity drugs at saturating concentrations. Receptor residence time (1/koff) determines duration of effect in some drug classes more than plasma half-life does (e.g., tiotropium, irreversible aspirin).
The concentration-response relationship is the cornerstone of quantitative pharmacology. The parameters derived from these curves, including the maximum effect, the concentration producing half-maximal effect, and the steepness of the relationship, define a drug's potency and efficacy in a system and provide the quantitative framework for comparing drugs, predicting interactions, and designing dosing strategies.
A graded concentration-response curve describes the relationship between drug concentration and the magnitude of a continuous, measurable pharmacological response in a single biological preparation (a cell, tissue, organ, or intact subject). The standard model predicts a sigmoidal relationship on a log-concentration axis, described by the Hill equation: E = Emax x [C]n / (EC50n + [C]n), where E is the effect at concentration [C], Emax is the maximum possible effect, EC50 is the concentration producing 50 percent of Emax, and n is the Hill coefficient (also called the slope factor or Hill slope). The Emax defines the ceiling of drug effect and is a property of the drug-receptor-effector system, reflecting the intrinsic efficacy of the drug and the maximum capacity of the effector pathway. Two drugs can differ in their Emax values even if they act at the same receptor: a full agonist achieves the system Emax, while a partial agonist achieves a submaximal Emax by definition, regardless of concentration.78
Potency versus Efficacy. The EC50 is the standard measure of drug potency: a drug with an EC50 of 1 nM is 100-fold more potent than a drug with an EC50 of 100 nM in the same system, because it produces the same half-maximal effect at a 100-fold lower concentration. Potency and efficacy are independent properties. Morphine and codeine both act as mu-opioid receptor agonists with the same Emax in terms of analgesic ceiling (both are full agonists in clinical use, though codeine is a prodrug), but morphine is approximately 10-fold more potent than codeine on an oral milligram-for-milligram basis. By contrast, buprenorphine is a partial mu-opioid agonist with very high receptor affinity (low Kd) and high potency (low EC50) but a lower Emax than morphine in terms of maximal analgesic effect in experimental pain models, illustrating that potency and efficacy reflect different receptor properties and do not vary together predictably.89
The Hill Coefficient. The Hill coefficient n describes the steepness of the concentration-response curve. When n = 1, the curve follows a simple hyperbola and an 81-fold increase in concentration is required to move from 10 percent to 90 percent of maximal effect. When n is greater than 1, the curve is steeper, with a smaller concentration range separating threshold and near-maximal effects; this is termed positive cooperativity and occurs when ligand binding to one receptor subunit or binding site facilitates binding to subsequent sites. The hemoglobin-oxygen binding curve, with n approximately 2.8, is the classic example. When n is less than 1, the curve is shallower than a simple hyperbola, indicating negative cooperativity. For most pharmacological receptors, n is close to 1. A steep Hill coefficient (n greater than 2) in a clinical drug response curve has practical consequences: a small increase in dose near the EC50 produces a disproportionate increase in effect, contributing to the narrow therapeutic index seen with drugs such as warfarin and digoxin.7
Quantal Dose-Response Curves. A quantal (all-or-none) dose-response curve describes the fraction of a population of subjects that exhibits a defined, discrete endpoint (e.g., sleep induction, seizure suppression, or death) at each dose. Unlike graded curves, which measure response intensity in one preparation, quantal curves reflect the distribution of thresholds across individuals in a population. When plotted cumulatively, they produce a sigmoidal curve similar in shape to the graded curve. The median effective dose (ED50) is the dose producing the quantal endpoint in 50 percent of subjects. The median lethal dose (LD50), derived from animal studies, is the dose producing death in 50 percent of animals. The therapeutic index (TI) is defined as LD50 (median lethal dose) divided by ED50 (median effective dose). A drug with a TI of 10 is safer (larger separation between effective and lethal doses) than a drug with a TI of 2. In clinical practice, the therapeutic index is approximated by the ratio of the minimum toxic concentration to the minimum effective concentration, or by the ratio of the dose producing toxicity in 5 to 10 percent of patients (TD5 or TD10) to the ED50.8
Efficacy (Emax): the maximum effect a drug can produce, determined by intrinsic efficacy and effector pathway capacity. Potency (EC50): the concentration required to produce half-maximal effect. A more potent drug is not inherently better clinically; it simply requires a lower concentration to achieve the same effect. High potency matters most when route of administration or formulation constraints limit deliverable dose. A partial agonist may be highly potent (low EC50) but have reduced efficacy (lower Emax) compared to a full agonist at the same receptor, which is clinically significant when maximum effect is required (e.g., severe acute pain).
Agonists are drugs that bind to receptors and produce a biological response. The magnitude of that response is determined not only by receptor occupancy but by the intrinsic efficacy of the drug, which reflects the ability of the drug-receptor complex to activate downstream effector systems. The spectrum of agonist intrinsic efficacy, from full agonists through partial agonists to inverse agonists, is clinically exploited in multiple therapeutic areas.
A full agonist is a drug that, at sufficiently high concentrations, produces the maximum response the receptor-effector system can generate (the system Emax). Full agonist status is system-dependent: a drug that is a full agonist in a tissue with high receptor density and robust effector coupling may behave as a partial agonist in a tissue where receptor density is lower or effector coupling is less efficient. The concept of intrinsic efficacy, introduced by Stephenson in 1956, quantified the ability of a drug-receptor complex to generate a stimulus per unit receptor occupancy, independent of receptor concentration.7 A full agonist has an intrinsic efficacy value of 1 (or the maximum value in a given normalization scheme), while a partial agonist has an intrinsic efficacy between 0 and 1, and a competitive antagonist has an intrinsic efficacy of 0.
Partial Agonists. A partial agonist binds to and activates a receptor but produces a submaximal response even when all available receptors are occupied. The clinical implications are dual and contextually dependent. When used alone (in the absence of an endogenous full agonist), a partial agonist produces a submaximal but definite pharmacological effect, which is therapeutically exploited when a ceiling effect is desirable. Buprenorphine, a partial mu-opioid receptor agonist with very high receptor affinity, illustrates this: its ceiling effect on respiratory depression is a safety advantage compared to full agonist opioids in opioid use disorder treatment, while its high affinity allows it to block full agonist opioids even in the setting of concurrent illicit use.9 When a partial agonist is introduced in the presence of a full agonist (including the endogenous ligand), it can compete with the full agonist for receptor occupancy and produce net antagonism, because the partial agonist-receptor complex is less efficacious than the full agonist-receptor complex it displaces. Aripiprazole, a partial agonist at dopamine D2 (dopamine receptor subtype 2) receptors, is a further example: in mesolimbic pathways where dopamine tone is high, aripiprazole acts as a functional antagonist, reducing dopaminergic signaling; in mesocortical pathways where dopamine tone is low, it provides net agonist activity.10
Inverse Agonists. Inverse agonists represent a class that became pharmacologically recognized only after the discovery that many receptors, particularly GPCRs, exhibit constitutive (ligand-independent) activity. A constitutively active receptor exists in a basal equilibrium between inactive (R) and spontaneously active (R*) conformations, producing measurable baseline signaling in the absence of any ligand. A neutral antagonist binds to both R and R* with equal affinity, blocking agonist access without altering the R to R* equilibrium and therefore reducing the effect of an agonist without changing basal signaling. An inverse agonist binds preferentially to the inactive R conformation, shifting the equilibrium away from R* and reducing constitutive activity below the basal level. Clinically, many drugs historically classified as antagonists are now recognized as inverse agonists. Beta-blockers such as metoprolol and carvedilol are inverse agonists at the beta-1 adrenergic receptor: they not only block catecholamine-stimulated receptor activation but also suppress the constitutive activity of the receptor that is elevated in heart failure, which may contribute to the clinical benefit of beta-blockers beyond simple sympathetic blockade.2
Partial agonists are pharmacological tools that provide submaximal activation with inherent ceiling effects. Key clinical examples: buprenorphine (partial mu-opioid agonist) for opioid use disorder treatment and pain; aripiprazole and brexpiprazole (partial D2 agonists) as atypical antipsychotics; buspirone (partial 5-HT1A agonist) for anxiety; varenicline (partial alpha-4-beta-2 nicotinic acetylcholine receptor agonist) for smoking cessation. When a partial agonist is combined with a full agonist, net effect depends on relative concentrations, receptor affinities, and intrinsic efficacy values. Buprenorphine's high receptor affinity means it displaces full agonist opioids from mu receptors even at therapeutic doses, precipitating withdrawal if administered to a physically dependent patient with full agonist opioids still receptor-bound.
Receptor antagonism is the pharmacological basis for a large proportion of clinical therapeutics. Understanding the distinctions between competitive reversible, competitive irreversible, and non-competitive antagonism is not merely academic: these mechanisms have distinct and consequential clinical differences in terms of dose-response curve shifts, reversibility, toxicity management, and drug interaction prediction.
A competitive reversible antagonist binds to the same orthosteric site on the receptor as the agonist and can be displaced by increasing agonist concentrations. The hallmark of competitive reversible antagonism on a log concentration-response curve is a parallel rightward shift of the agonist curve with no change in Emax. The degree of rightward shift is directly proportional to the antagonist concentration and inversely proportional to the antagonist affinity (Kd for the antagonist). Quantitatively, the dose ratio (DR) is defined as the concentration of agonist required to produce a given effect in the presence of antagonist divided by the concentration required in the absence of antagonist. At equilibrium: DR = 1 + [B]/KB, where [B] is the antagonist concentration and KB (the equilibrium dissociation constant for the antagonist) describes the antagonist's affinity for the receptor. This is the Gaddum equation, and it predicts that competitive reversible antagonism is surmountable by increasing agonist concentration. Clinically, this means that the antagonistic effect of naloxone on opioid-induced respiratory depression can be overcome by very high opioid doses, and that the antihypertensive effects of losartan (competitive angiotensin II type 1 receptor, AT1R, antagonist) can theoretically be overcome by very high angiotensin II levels as occur in high-renin states, though this is rarely clinically significant at standard doses.11
Schild Analysis and pA2. Schild analysis provides a method to determine the KB of a competitive antagonist from functional pharmacological data. By measuring the dose ratios at multiple antagonist concentrations, a Schild plot of log(DR-1) versus log[B] is constructed; a slope of 1.0 confirms competitive reversible antagonism, and the x-intercept gives the log KB, with the negative log KB defined as the pA2 value. A pA2 of 9 means the antagonist has a KB of 1 nM (10-9 M), indicating very high affinity. The pA2 is a system-independent measure of antagonist affinity and is one of the few truly system-independent pharmacological parameters. Schild analysis is still used in drug discovery to confirm binding mode and measure antagonist potency for receptor characterization.11
Competitive Irreversible Antagonism. Competitive irreversible antagonists (also called non-equilibrium competitive antagonists or pseudo-irreversible antagonists) bind to the same orthosteric site as the agonist but with such a slow koff that, for practical purposes within the pharmacological time frame, receptor occupancy by the antagonist is not reversible by increasing agonist concentration. The consequence on the log concentration-response curve is qualitatively different from reversible competitive antagonism: initially, a parallel rightward shift occurs (when receptor reserve is present), but as more receptors are irreversibly blocked, the Emax progressively decreases because the number of receptors available for agonist-induced activation is reduced below the threshold required for maximal response. Phenoxybenzamine, an irreversible alpha-adrenergic antagonist used in pheochromocytoma management, illustrates this: it covalently alkylates the alpha-1 and alpha-2 adrenergic receptors, producing a long-duration (24 to 48 hours) blockade that cannot be overcome by catecholamine surges from the tumor. The duration of action is determined by receptor synthesis rather than drug elimination.11
Non-Competitive Antagonism and Allosteric Modulation. Non-competitive antagonists bind to a site on the receptor distinct from the orthosteric agonist binding site (an allosteric site), reducing the ability of the agonist-receptor complex to activate downstream effectors without interfering with agonist binding. The concentration-response curve consequence is a depression of Emax without a parallel rightward shift, even though agonist binding is not directly blocked. Channel pore blockers represent a mechanistically distinct but functionally similar category: drugs such as ketamine (NMDA [N-methyl-D-aspartate] receptor pore blocker) and memantine enter and block the open channel pore, reducing the efficacy of glutamate-mediated channel activation in a use-dependent manner. Negative allosteric modulators (NAMs) reduce agonist efficacy and/or potency, while positive allosteric modulators (PAMs) enhance agonist efficacy and/or potency without activating the receptor on their own. Benzodiazepines are PAMs at the GABA-A (gamma-aminobutyric acid type A) receptor: they enhance the frequency of chloride channel opening in response to GABA (gamma-aminobutyric acid) without opening the channel in the absence of GABA, which accounts for their safety advantage over barbiturates, which can open the GABA-A channel independently of GABA at high concentrations.23
Competitive reversible antagonism: effect surmountable by increasing agonist concentration; overdose of antagonist reversed by administering agonist (e.g., naloxone reverses opioid toxicity). Competitive irreversible antagonism: effect not surmountable; duration determined by receptor resynthesis (days); use in clinical settings requires accepting prolonged blockade (phenoxybenzamine). Non-competitive/allosteric antagonism: Emax depressed, not shifted; not surmountable by increasing agonist. Positive allosteric modulation (PAMs): can produce supra-physiological receptor activation in the presence of endogenous agonist; benzodiazepine PAM activity at GABA-A limits Emax by requiring GABA co-presence.
One of the most clinically important and conceptually counterintuitive findings in receptor pharmacology is that many tissues contain far more receptors than are needed to produce a maximal response. This receptor reserve, or population of spare receptors, has profound consequences for drug potency estimation, the interpretation of partial agonist behavior, and the clinical effects of irreversible receptor blockade.
Receptor reserve was first systematically described by Stephenson in 1956 and elaborated by Furchgott in subsequent years. The central observation is that in tissues with receptor reserve, the EC50 (the concentration producing 50 percent of maximum effect in a functional assay) of a full agonist on a concentration-effect curve is substantially lower than the Kd measured in a binding assay. A tissue may reach its maximum contractile or secretory response when only 1 to 10 percent of available receptors are occupied. The reason is not that the remaining receptors are doing nothing: the signal transduction cascade (G protein activation, second messenger generation, protein kinase activation) amplifies the initial receptor signal enormously, so that the effector pathway is saturated at a small fraction of maximal receptor occupancy. The receptors beyond this threshold are "spare" in the sense that occupying them by increasing agonist concentration produces no additional response once the effector pathway is already saturated.67
Consequences for Potency Estimation. In tissues with large receptor reserves, a full agonist appears much more potent (has a lower EC50 relative to its Kd) than in tissues with small receptor reserves. This means that EC50 values measured in functional assays are tissue-dependent and should not be used as estimates of receptor affinity (Kd) unless the absence of receptor reserve is specifically established. Receptor reserve varies considerably across tissues and across receptor subtypes within the same tissue, which explains why the same agonist can have dramatically different apparent potencies in different organ preparations even when the receptor subtype is identical. This is of direct clinical relevance: the marked potency of fentanyl at opioid receptors in producing respiratory depression relative to analgesia partly reflects differences in receptor reserve and effector coupling efficiency between respiratory control centers and nociceptive pathways.6
Receptor Reserve and Partial Agonists. Receptor reserve also determines whether a partial agonist behaves as an agonist or an antagonist in a given tissue. In a tissue with large receptor reserve, a partial agonist may produce a maximal effect at a receptor occupancy (e.g., 50 percent) that would be only a fraction of the reserve needed; the partial agonist-receptor complex is less efficacious per receptor, but if enough receptors are available, maximal tissue response can still be achieved. In a tissue with little or no receptor reserve, the same partial agonist will fail to produce a maximal response because the lower intrinsic efficacy of the drug-receptor complex is not amplified sufficiently. This explains why buprenorphine demonstrates ceiling effects on respiratory depression (a pathway with limited receptor reserve for opioid-induced depression) while still producing meaningful analgesia (a pathway with greater opioid receptor reserve and amplification).9
Receptor Reserve and Irreversible Antagonism. The existence of receptor reserve means that irreversible blockade of a fraction of receptors may produce no detectable change in Emax if the remaining unblocked receptors are still sufficient to saturate the effector pathway. Only when irreversible blockade reduces available receptors below the minimum needed for maximal response does the Emax begin to fall. This creates a pharmacological buffer against the effects of irreversible receptor inactivation. Experimentally, this was demonstrated by Furchgott using phenoxybenzamine to progressively and irreversibly block alpha-adrenergic receptors in smooth muscle preparations: no change in Emax occurred until a critical fraction of receptors was blocked, after which Emax fell steeply. The size of the receptor reserve can be calculated from the degree of irreversible blockade required to begin depressing the Emax. In clinical medicine, this buffer operates when aspirin irreversibly inactivates COX-1 (cyclooxygenase-1) in platelets: platelet thromboxane A2 (TXA2) production for aggregation is suppressed even though some COX-1 molecules remain active, because the pathway operates with receptor and enzyme reserve.1112
EC50 (functional) is lower than Kd (binding) whenever receptor reserve is present. Large receptor reserve means: (1) agonist is more potent in functional assays than binding assays predict; (2) partial agonists may produce full responses in tissues with large reserve; (3) irreversible blockade of a fraction of receptors may have no effect on Emax until reserve is exhausted. Low-dose aspirin (81 mg daily) achieves near-complete platelet COX-1 inhibition because TXA2 synthesis has virtually no reserve; in contrast, prostacyclin production in vascular endothelium (anti-aggregatory) requires more substantial COX inhibition to be suppressed, providing the mechanistic basis for low-dose aspirin selectivity for platelet inhibition.
Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov. 2006;5(12):993-996.
doi:10.1038/nrd2199Gilman AG. G proteins: transducers of receptor-generated signals. Annu Rev Biochem. 1987;56:615-649.
doi:10.1146/annurev.bi.56.070187.003151Sieghart W. Structure, pharmacology, and function of GABA-A receptor subtypes. Adv Pharmacol. 2006;54:231-263.
doi:10.1016/S1054-3589(06)54010-4Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade. Cell. 1995;83(6):835-839.
doi:10.1016/0092-8674(95)90199-XMotulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol Pharmacol. 1984;25(1):1-9.
doi:10.1016/S0026-895X(25)15016-5Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov. 2006;5(9):730-739.
doi:10.1038/nrd2082Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother. 1956;11(4):379-393.
doi:10.1111/j.1476-5381.1956.tb00006.xKenakin T. What is pharmacological 'affinity'? Relevance to biased agonism and antagonism. Trends Pharmacol Sci. 2014;35(9):434-441.
doi:10.1016/j.tips.2014.06.003Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949-958.
doi:10.1056/NEJMoa022164Mailman RB. GPCR functional selectivity has therapeutic impact. Trends Pharmacol Sci. 2007;28(8):390-396.
doi:10.1016/j.tips.2007.06.002Kenakin T. Functional selectivity and biased receptor signaling. J Pharmacol Exp Ther. 2011;336(2):296-302.
doi:10.1124/jpet.110.173948Furchgott RF. The use of beta-haloalkylamines in the differentiation of receptors and in the determination of dissociation constants of receptor-agonist complexes. Adv Drug Res. 1966;3:21-55. Academic Press, London.